CMEI mAbs Cover

NEW BRIEF: Regulatory Roadblocks Hinder Development of New COVID-19 Treatments for the Immuno­compromised

The current federal regulatory process to develop monoclonal antibodies to treat mutating strains of COVID-19 imposes unnecessary hurdles that hinder the creation and approval of effective treatments for the immunocompromised, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. Click to download the brief “Monoclonal antibodies provided benefits to vulnerable populations and six different ones were authorized to treat COVID-19,” said Dr. Wayne Winegarden, ...
PBM IssueBrief CMEI Feb24 F

NEW BRIEF: End Anti-Market Distortions in Current PBM System Would Lower Patient Costs, Increase Access to Life-Saving Drugs

SACRAMENTO – Fixing the current broken system that incentivizes pharmacy benefit managers (PBMs) to enact policies that benefit themselves and insurers at the expense of patients would lead to lower patient drug costs, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. Click to download the brief “The current system incentivizes PBMs to implement policies that benefit insurers and themselves, while making drugs less ...
health 13983450163 4ed837247f o

Small-Molecule Price Controls Are Short-Sighted

There’s never been a better time to get lung cancer in the United States. That may sound morbid. But this deadliest of cancers appears to be losing a bit of its punch. The combination of smoking reduction, increased screening, and pharmaceutical advancements has caused the lung cancer death rate to drop 20% over the past five years, according to reporting from the Wall Street Journal earlier this month. The last leg of that three-legged stool is the most ...

Trending Topics

Studies

Biosimilars June2024 rFCover
IssueBriefDebukingBarber cover
CMEI mAbs Cover
PBM IssueBrief CMEI Feb24 F
CapIdeasWebImagePortrait PipesAgenda
CMEI CovidF COVER1
CoverageDeniedCoversforWeb8
CoverageDeniedCover7
340B Policy2022 F
CoverageDeniedCoversforWeb6
CACapital
BiosimilarsCompetition F Cover 2
Scroll to Top